Reliable Laboratory Testing
Reliable Diagnostic and Antibody Testing Solutions
Our commitment to the health and well-being of our customers extends to their employees, family, and friends. That’s why we’ve chosen US BioTek Laboratories as our preferred provider for laboratory testing solutions.
For over 30 years, their innovative laboratory testing has provided clinicians worldwide with the tools they need to develop effective care plans for patients. With rigorous quality controls, advanced laboratory technology, and fast turnaround times, they can be trusted to provide accurate, reliable, and timely results.
COVID-19 Diagnostic Testing
US BioTek uses Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests to detect RNA from SARS-CoV-2, as recommended by the CDC. The RT-PCR platform is FDA-authorized and requires specialized equipment and personnel to identify the viral RNA within cells. This type of testing is considered more accurate than most “rapid” tests. The specificity of the RT-PCR is tested weekly to ensure that newly discovered COVID-19 mutations are detected by the test.
PCR is a widely used molecular biology technique to amplify and detect DNA and RNA sequences. PCR is a highly sensitive method and uses very small sample volumes to rapidly make millions of copies of a specific RNA sample. This allows scientists to take a very small sample of RNA and amplify it to a large enough amount to study in detail.
COVID-19 Antibody Testing
The COVID-19 antibody test is a seral (blood) test designed to detect immunoglobulins, IgG and IgM, that are antibodies against the coronavirus that causes COVID-19. US Biotek runs their COVID-19 antibody tests on high-precision immunoassay analyzers that utilize enzyme-amplified chemiluminescence technology (CLA). The antibody test utilizes this highly sensitive technique to detect even very small amounts of IgM and IgG antibodies for SARS-CoV-2. These machines are developed and manufactured in the US and offer the most accurate COVID-19 antibody testing currently available.
The COVID-19 antibody screen has an overall specificity of 99.8% and a sensitivity of 100% at >14 days post-infection. In a human study of COVID-19 patients, the COVID-19 IgG + IgM antibody panel was found to have a clinical sensitivity of 95.5% and a clinical specificity of 96%.
